Evidence map›Paper›PMID 24027427›Full record

ArticleNeoplasia (New York, N.Y.)2013

Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice.

Chinthalapally V Rao, Jagan Mohan R Patlolla, Li Qian, Yuting Zhang, Misty Brewer, Altaf Mohammed, Dhimant Desai, Shantu Amin, Stan Lightfoot, Levy Kopelovich

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Chinthalapally V RaoCenter for Cancer Prevention and Drug Development, Hematology-Oncology Section, Department of Medicine, Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Jagan Mohan R Patlolla
Li Qian
Yuting Zhang
Misty Brewer
Altaf Mohammed
Dhimant Desai
Shantu Amin
Stan Lightfoot
Levy Kopelovich
University of Oklahoma Health Sciences Center · USPenn State Milton S. Hershey Medical Center · USOklahoma City VA Medical Center · USPrevention Group · US

Funding

NCI NIH HHS CN-53300NCI NIH HHS N01 CN053300NCI NIH HHS N02-CB-81013-74
6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer deaths worldwide. Expression of the p53 tumor suppressor protein is frequently altered in tobacco-associated lung cancers. We studied chemopreventive effects of p53-modulating agents, namely, CP-31398 and Prima-1, on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung adenoma and adenocarcinoma formation in female A/J mice. Seven-week-old mice were treated with a single dose of NNK (10 µmol/mouse) by intraperitoneal injection and, 3 weeks later, were randomized to mice fed a control diet or experimental diets containing 50 or 100 ppm CP-31398 or 150 or 300 ppm Prima-1 for either 17 weeks (10 mice/group) or 34 weeks (15 mice/group) to assess the efficacy against lung adenoma and adenocarcinoma. Dietary feeding of 50 or 100 ppm CP-31398 significantly suppressed (P < .0001) lung adenocarcinoma by 64% and 73%, respectively, after 17 weeks and by 47% and 56%, respectively, after 34 weeks. Similarly, 150 or 300 ppm Prima-1 significantly suppressed (P < .0001) lung adenocarcinoma formation by 56% and 62%, respectively, after 17 weeks and 39% and 56%, respectively, after 34 weeks. Importantly, these results suggest that both p53 modulators cause a delay in the progression of adenoma to adenocarcinoma. Immunohistochemical analysis of lung tumors from mice exposed to p53-modulating agents showed a significantly reduced tumor cell proliferation and increased accumulation of wild-type p53 in the nucleus. An increase in p21- and apoptotic-positive cells was also observed in lung tumors of mice exposed to p53-modulating agents. These results support a chemopreventive role of p53-modulating agents in tobacco carcinogen-induced lung adenocarcinoma formation.

Indexed as

AdenocarcinomaAnimalsAnticarcinogenic AgentsApoptosisAza CompoundsBridged Bicyclo Compounds, HeterocyclicCell Transformation, NeoplasticChemopreventionCyclin-Dependent Kinase Inhibitor p21FemaleLung NeoplasmsMiceMice, Inbred ANitrosaminesPyrimidinesRandom Allocation2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneAnticarcinogenic AgentsAza CompoundsBridged Bicyclo Compounds, HeterocyclicCP 31398Cyclin-Dependent Kinase Inhibitor p21NitrosaminesPyrimidinesTumor Suppressor Protein p53

Identifiers

PMID24027427
PMCPMC3769881
OpenAlexW1648151452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.